Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cripto expression in human urological tumors

E Okajima1, M Tsutsumi, E Okajima

  • 1Department of Oncological Pathology, Cancer Center, Nara Medical University, Shijyo-cho, Kashihara, Japan.

Cancer Letters
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated concepts and treatment of carcinoma in situ.

Urologic oncology·2011
Same author

Induction of tumor regression by passive transfer of antibody from mice vaccinated with anti-idiotype antibodies resembling a human renal cell carcinoma-associated antigen.

Urologic oncology·2011
Same author

Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.

Aktuelle Urologie·2003
Same author

Detection of circulating MN/CA9 positive renal cell carcinoma cells during operation.

Aktuelle Urologie·2003
Same author

Treated natural history of superficial bladder cancer.

Japanese journal of clinical oncology·2002
Same author

Transurethral needle ablation of the prostate: an initial Japanese clinical trial.

International journal of urology : official journal of the Japanese Urological Association·2001
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same journal

Corrigendum to "Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice" [Cancer Lett. (2022) 31 529 53-69].

Cancer letters·2026
See all related articles

Cripto gene expression was investigated in various urological tumors. This study found limited cripto expression in bladder and adrenal cancers, suggesting it is not common in these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • Cripto is a transforming gene within the epidermal growth factor superfamily.
  • Understanding gene expression in tumors is crucial for diagnosis and treatment.

Purpose of the Study:

  • To examine the expression of the cripto gene in a variety of urological tumors.
  • To determine the prevalence of cripto expression in different types of urological malignancies.

Main Methods:

  • Immunohistochemical analysis was employed to detect cripto expression.
  • The study analyzed tumor samples from urinary bladder, ureter, renal pelvis, kidney, prostate, adrenal gland, and testes.

Main Results:

  • Positive cripto staining was observed in three cases of urinary bladder transitional cell carcinoma (two grade 2, one grade 3) and one adrenal cortical carcinoma.

Related Experiment Videos

  • No cripto expression was detected in tumors of the ureter, renal pelvis, kidney, prostate, or testes.

    • Conclusions:

    • Cripto expression is infrequent in the analyzed urological tumors.
    • The findings suggest cripto is not a common biomarker in most urological cancers.